The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling

During kidney fibrosis, a hallmark and promoter of CKD (regardless of the underlying renal disorder leading to CKD), the extracellular-regulated kinase 1/2 (ERK1/2) pathway, is activated and has been implicated in the detrimental differentiation and expansion of kidney fibroblasts. An ERK1/2 pathway...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2019-01, Vol.30 (1), p.33-49
Hauptverfasser:	Andrikopoulos, Petros, Kieswich, Julius, Pacheco, Sabrina, Nadarajah, Luxme, Harwood, Steven Michael, O'Riordan, Caroline E, Thiemermann, Christoph, Yaqoob, Muhammad M
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Basic Research Biopsy, Needle Cells, Cultured Disease Models, Animal Extracellular Signal-Regulated MAP Kinases - drug effects Extracellular Signal-Regulated MAP Kinases - genetics Fibroblasts - drug effects Fibrosis - drug therapy Fibrosis - pathology Immunohistochemistry Mechanistic Target of Rapamycin Complex 1 - drug effects Mechanistic Target of Rapamycin Complex 1 - genetics Mice Molecular Targeted Therapy - methods Pyridones - pharmacology Pyrimidinones - pharmacology Random Allocation Reference Values Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - genetics Renal Insufficiency, Chronic - pathology Signal Transduction - drug effects Signal Transduction - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!